Copyright © 2025 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

@article{157684,
        author = {Geethika Pravanya Alla and Pallagolla Harika and Harshitha Nagothu},
        title = {EVALUATING DRUG SAFETY IN THE ERA OF COVID-19: A REVIEW OF PHARMACOVIGILANCE PRACTICES},
        journal = {International Journal of Innovative Research in Technology},
        year = {},
        volume = {9},
        number = {7},
        pages = {752-759},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=157684},
        abstract = {The COVID-19 pandemic has led to the rapid development and widespread use of various medications to treat and prevent the virus. As with any new drug, it is important to carefully assess the safety and effectiveness of the treatments. This review aims to examine pharmacovigilance practices for evaluating drug safety in the context of COVID-19. We begin by defining pharmacovigilance, its functions and importance during the pandemic era. This report also discusses about various types of data sources used in pharmacovigilance, including spontaneous reporting systems, clinical trials, and observational studies. Finally, conclude with the challenges and limitations of pharmacovigilance during the COVID-19 pandemic and suggested strategies for improving drug safety monitoring in this rapidly evolving situation. Overall, this article highlights the crucial role of pharmacovigilance in ensuring safe and effective use of medications in the fight against COVID-19.},
        keywords = {COVID-19, pharmacovigilance, drug safety assessment.},
        month = {},
        }